A security analysis is not yet prepared for this market.
The next payment has not been announced
The series is stated in the current share scale after splits; dividends are not included in the price
Bio-Techne makes the proteins and reagents biological experiments are assembled from.
A researcher needs antibodies, growth factors and assay kits — consumables bought continuously that cost little relative to the experiment itself. A spoiled reagent, however, destroys months of work, so a laboratory is not tempted to economise or change supplier.
The growing part is materials for manufacturing cell and gene therapies: the same proteins, but made to pharmaceutical standards and written into a drug's registration dossier. Such a position is locked in for the medicine's whole life. Risks: funding for science and biotech start-ups, demand in China. A single reagent is inexpensive, but a laboratory buys hundreds of them, and the range itself is what holds the customer. The dividend is token.
Based on the fiscal year ended 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Bio-Techne Corp (TECH) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Bio-Techne Corp (TECH) on November 3, 2026 is 72.69 $, +0.03 % on the day. Over the past year the price changed by +21.72 %. The P/E ratio is 62.39, which is above the sector median (24.61). Market capitalization is 11.35 billion $, rank 9 among 132 stocks of the same industry with a known capitalization.
Bio-Techne Corp trades on Nasdaq under the ticker TECH. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks TECH has traded between 43.20 $ and 72.69 $. As of 3 November 2026 the price stood 99.42 % of the way from the 52-week low to the high.
Over one year TECH shares rose 21.72 %; over six months they rose 26.43 %. Volatility over 90 days is 35.46 %. Dividends are not included: this is price change only, as of 3 November 2026.
TECH trades at a price-to-earnings ratio of 62.4, above the sector median of 24.6. Price to sales is 9.3, above the sector median of 3.6. Price to book is 5.4, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Bio-Techne Corp reported revenue of 1.2B $ and net income of 182M $ for the latest fiscal year. Net margin is 14.97 %. Revenue changed by −0.38 % year over year. Earnings per share are 1.16 $. Market capitalisation is 11.3B $.
TECH has a return on equity of 8.63 %, above the sector median of −40.58 %. Return on assets is 7.03 %, above the sector median of −30.08 %. Operating margin is 20.73 %, above the sector median of −20.96 %.
Bio-Techne Corp pays dividends quarterly: 0.32 $ per share over the past twelve months, a yield of 0.44 %. The latest payment was 0.0800 $, with an ex-dividend date of 24 August 2026.
